MENU
+Compare
ALPMY
Stock ticker: OTC
AS OF
Jun 5 closing price
Price
$9.66
Change
-$0.21 (-2.13%)
Capitalization
26.55B

ALPMY Astellas Pharma, Inc. Forecast, Technical & Fundamental Analysis

Astellas Pharma Inc is a specialty global pharmaceutical company... Show more

ALPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ALPMY with price predictions
Jun 05, 2025

ALPMY's RSI Indicator recovers from oversold territory

The RSI Indicator for ALPMY moved out of oversold territory on May 15, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 46 similar instances when the indicator left oversold territory. In of the 46 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 23, 2025. You may want to consider a long position or call options on ALPMY as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ALPMY just turned positive on May 23, 2025. Looking at past instances where ALPMY's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

ALPMY moved above its 50-day moving average on May 22, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ALPMY crossed bullishly above the 50-day moving average on May 30, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALPMY advanced for three days, in of 287 cases, the price rose further within the following month. The odds of a continued upward trend are .

ALPMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 188 cases where ALPMY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 64 cases where ALPMY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALPMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.427) is normal, around the industry mean (5.632). P/E Ratio (37.594) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.004). Dividend Yield (0.030) settles around the average of (0.161) among similar stocks. P/S Ratio (2.448) is also within normal values, averaging (3.643).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ALPMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALPMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock worse than average.

View a ticker or compare two or three
ALPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ALPMY is expected to report earnings to fall 42.34% to 16 cents per share on July 30

Astellas Pharma, Inc. ALPMY Stock Earnings Reports
Q2'25
Est.
$0.17
Q1'25
Beat
by $0.16
Q4'24
Missed
by $0.41
Q3'24
Beat
by $0.01
Q2'24
Beat
by $0.08
The last earnings report on April 25 showed earnings per share of 29 cents, beating the estimate of 13 cents. With 181.29K shares outstanding, the current market capitalization sits at 26.55B.
A.I.Advisor
published Dividends

ALPMY paid dividends on June 17, 2024

Astellas Pharma, Inc. ALPMY Stock Dividends
А dividend of $0.22 per share was paid with a record date of June 17, 2024, and an ex-dividend date of March 27, 2024. Read more...
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
N/A
Address
2-5-1, Nihonbashi-Honcho
Phone
+81 332443000
Employees
16243
Web
http://www.astellas.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DRTCX19.24N/A
N/A
BNY Mellon Sust US Equity I
OLVAX20.10N/A
N/A
JPMorgan Large Cap Value A
MGPIX103.45N/A
N/A
ProFunds Mid Cap Growth Inv
GGGPX40.49N/A
N/A
Goldman Sachs Large Cap Equity P
BUIMX16.90N/A
N/A
Buffalo Mid Cap Growth Inst

ALPMY and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ALPMY has been loosely correlated with ALPMF. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ALPMY jumps, then ALPMF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALPMY
1D Price
Change %
ALPMY100%
-2.13%
ALPMF - ALPMY
38%
Loosely correlated
N/A
OPHLY - ALPMY
33%
Loosely correlated
-1.13%
CHGCY - ALPMY
22%
Poorly correlated
-1.35%
DSNKY - ALPMY
21%
Poorly correlated
-5.07%
OTSKY - ALPMY
20%
Poorly correlated
-0.99%
More